Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05882058 | DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | recruiting | Phase 2 | 204 | Boehringer IngelheimINDUSTRY | 12 | Jul 23, 2026 |
| clinicaltrials |
| NCT06437509 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 66 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06475300 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 570 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07632365 | Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 108 | Shanghai Chest HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03485209 | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors(innovaTV 207) | active not recruiting | Phase 2 | 350 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 22, 2026 | clinicaltrials |
| NCT04166487 | Plasma-Adapted First-Line Pembro In NSCLC | active not recruiting | Phase 2 | 40 | Julia K. Rotow, MDOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05060016 | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)(DeLLphi-301) | active not recruiting | Phase 2 | 222 | AmgenINDUSTRY | 18 | Jul 22, 2026 | clinicaltrials |
| NCT05256290 | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations | active not recruiting | Phase 1 / Phase 2 | 200 | Black Diamond Therapeutics, Inc.INDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06003231 | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | active not recruiting | Phase 2 | 120 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 22, 2026 | clinicaltrials |
| NCT06902272 | ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer(DNA-PREDICT) | recruiting | Phase 2 | 30 | University of MiamiOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07720167 | Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 38 | Medical University of South CarolinaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05098132 | Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers(SYNERGY-101) | recruiting | Phase 1 / Phase 2 | 364 | SynthekineINDUSTRY | 4 | Jul 21, 2026 | clinicaltrials |
| NCT06088771 | Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC | recruiting | Phase 1 / Phase 2 | 21 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06996782 | A Platform Study in Non-Small Cell Lung Cancer (NSCLC)(ALTAIR) | recruiting | Phase 1 / Phase 2 | 152 | AstraZenecaINDUSTRY | 20 | Jul 21, 2026 | clinicaltrials |
| NCT07253142 | A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer | recruiting | Phase 2 | 120 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07559786 | A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy(ARL-LS-SCLC) | recruiting | Phase 2 | 200 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04285671 | Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05692635 | Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance | recruiting | Phase 2 | 60 | Wake Forest University Health SciencesOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 67 | University of California, IrvineOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT02525757 | MPDL3280A With Chemoradiation for Lung Cancer | active not recruiting | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03225664 | Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced | active not recruiting | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05705492 | Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer | recruiting | Phase 2 | 66 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06060613 | Safety and Efficacy of OBX-115 in Advanced Solid Tumors(Agni-01) | recruiting | Phase 1 / Phase 2 | 208 | Obsidian Therapeutics, Inc.INDUSTRY | 2 | Jul 16, 2026 | clinicaltrials |
| NCT07149649 | Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 / Phase 3 | 230 | Swiss Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07306624 | Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer | recruiting | Phase 2 | 62 | STCube, Inc.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07709585 | Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients(BE-MASTER) | not yet recruiting | Phase 2 | 124 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04407247 | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04922658 | Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 76 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05652686 | A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | recruiting | Phase 1 / Phase 2 | 203 | Phanes TherapeuticsINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05800015 | A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 / Phase 3 | 160 | Regeneron PharmaceuticalsINDUSTRY | 10 | Jul 15, 2026 | clinicaltrials |
| NCT07405190 | Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC | recruiting | Phase 2 | 46 | Massachusetts General HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07653438 | In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy(PulmoPrint) | not yet recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07704645 | The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 180 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.(MEDIOLA) | active not recruiting | Phase 1 / Phase 2 | 264 | AstraZenecaINDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT04995523 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC(ARTEMIDE-01) | active not recruiting | Phase 1 / Phase 2 | 212 | AstraZenecaINDUSTRY | 16 | Jul 14, 2026 | clinicaltrials |
| NCT07669779 | A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 348 | AkesoINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07703228 | Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC | active not recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07535437 | A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 66 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07698054 | Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer | not yet recruiting | Phase 2 | 130 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07699328 | A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer(REACH-EGFR) | recruiting | Phase 1 / Phase 2 | 315 | Voronoi, IncINDUSTRY | 10 | Jul 13, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07355205 | First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer(FLINN) | recruiting | Phase 1 / Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07452224 | ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 80 | iLeukon Therapeutics, Inc.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05937906 | Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.(IMMUNOMEK) | recruiting | Phase 1 / Phase 2 | 24 | Centre Georges Francois LeclercOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06502977 | Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment(DeLLphi-307) | active not recruiting | Phase 2 | 32 | AmgenINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07174583 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 262 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05003037 | Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 106 | Li Zhang, MDOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05543330 | A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC | recruiting | Phase 1 / Phase 2 | 116 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07242547 | Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients(MERLIN) | recruiting | Phase 2 | 37 | Fundación GECPOTHER | 1 | Jul 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 24, 2026source: clinicaltrials